Home» International» Foreign Expert

Professor : Yang Zhiwei

 

 

B.S. in chemistry, Peking University, 1991; M.S. in radio chemistry, Peking University, 1994; Ph.D. in organic chemistry, Columbia University, 1999

 

Postdoc in chemical biology at California Institute of Technology and Harvard University.  Associate principal scientist at Schering Plough Research Institute (SPRI, now Merck) and senior staff scientist/senior manager at Life Technologies in US.  Professor and Director of Major Disease Early Detection Platform at BUCT (current).

 

Chief achievements: (1)Established rapid mixture-based hit/lead optimization technology at SPRI, discover and quickly optimized lead series for cancers, metabolic diseases and infectious diseases.  (2) Invented series of highly potent transfection reagents.  In charged series Lipofectamine reagents (more than $100M/year sales) at Life Technologies.  Invented liver-targeting siRNA drug delivery system which is licensed by several world leading pharmaceutical companies.  (3) Collaborated with City of Hope and invented detection methods for 100+ diseases by next-generation sequencing (NGS).

 

My research interest is precision medicine. With the rapid development of NGS technology and targeted drug delivery It has three major directions: (1) Early detection of cancers by NGS.  Now we are studying the genetic mechanism of precancerous lesions and developing new technologies for the early detection of cancers.  (2)  Targeted drug delivery, including liver and cancer targeting drug delivery systems for siRNA, peptide, and small molecule drugs.

 

Basic biomedical research for the past 30 years unraveled the mechanisms of many diseases in molecular details.  With the emerging of next-generation sequencing technologies for the past 10 years, now we can quickly and economically study clinical samples and give medical doctors useful guidance in unprecedented accuracy.  Precision medicine is rapidly changing every part of medical practice, and give new hope to cancers, inherited diseases, cardiovascular diseases, etc.  It will be the most productive area in research and clinical practice.

| | Source: International Exchanges and Cooperation Department | Date: 2015-12-09